膀胱肿瘤化疗及分子靶向治疗的进展

被引：3

作者：

卢仙明

王健

机构：

[1] 青海大学附属医院泌尿外科

来源：

现代泌尿生殖肿瘤杂志 | 2014年 / 6卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R737.14 [膀胱肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

<正>膀胱癌是我国泌尿外科最常见的恶性肿瘤,占全部恶性肿瘤的3.2%,在世界范围内居恶性肿瘤的前10位[1]。据统计,2008年全世界新发膀胱癌386 300例,并有150 200例死于膀胱癌,全世界各国膀胱癌发病率随地区而异,其中埃及膀胱癌发病率最高(37/10 000),我国膀胱癌发病率略低于欧美国家[2]。但随着环境因素的影响和人们生活习惯的改变,我国膀胱癌的发病率也在逐年增加[3]。

引用

页码：183 / 185

页数：3

共 14 条

[1]

卡介苗、羟基喜树碱、表柔比星膀胱内灌注化疗预防膀胱癌术后复发的疗效评价 [J].

武斌 ;

陆向东 ;

李建华 ;

苏燕胜 ;

陈勇 .

现代泌尿外科杂志, 2012, 17 (06) :568-570

[2]

羟喜树碱与卡介苗预防膀胱癌术后复发的研究 [J].

殷明洲 .

中国现代医生, 2009, 47 (15) :31-32

[3]

多种药物联合膀胱灌注预防膀胱癌复发的临床研究 [J].

周天贵 ;

周承贵 ;

宋兴福 ;

袁红纲 ;

陈先国 .

现代泌尿生殖肿瘤杂志, 2009, 1 (02) :91-93

[4]

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study [J].

Wu, Yi-Long ;

Fukuoka, Masahiro ;

Mok, Tony S. K. ;

Saijo, Nagahiro ;

Thongprasert, Sumitra ;

Yang, James C. H. ;

Chu, Da-Tong ;

Yang, Jin-Ji ;

Rukazenkov, Yuri .

LUNG CANCER, 2013, 81 (02) :280-287

[5]

Investigational cell cycle inhibitors in clinical trials for bladder cancer [J].

Yun, Seok Joong ;

Moon, Sung-Kwon ;

Kim, Wun-Jae .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) :369-377

[6]

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

[7]

Contemporary Use of Perioperative Cisplatin-Based Chemotherapy in Patients With Muscle-Invasive Bladder Cancer [J].

Raj, Ganesh V. ;

Karavadia, Saumil ;

Schlomer, Bruce ;

Arriaga, Yull ;

Lotan, Yair ;

Sagalowsky, Arthur ;

Frenkel, Eugene .

CANCER, 2011, 117 (02) :276-282

[8]

Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? [J].

Kassouf, Wassim ;

Brown, Gordon A. ;

Black, Peter C. ;

Fisher, Mark B. ;

Inamoto, Teruo ;

Luongo, Tony ;

Gallagher, David ;

Bar-Eli, Menashe ;

McConkey, David J. ;

Adam, Liana ;

Dinney, Colin P. N. .

JOURNAL OF UROLOGY, 2008, 180 (03) :1146-1153

[9]

Muscle-Invasive Urothelial Carcinoma of the Bladder.[J].S. Bruce Malkowicz;Hendrik van Poppel;Gerald Mickisch;Vito Pansadoro;Joachim Thüroff;Mark S. Soloway;Sam Chang;Mitchell Benson;Iwao Fukui.Urology.2007, 1

[10]

Delay in the surgical treatment of bladder cancer and survival: Systematic review of the literature [J].

Fahmy, Nader M. ;

Mahmud, Salaheddin ;

Aprikian, Armen G. .

EUROPEAN UROLOGY, 2006, 50 (06) :1176-1182

← 1 2 →